Literature DB >> 15985574

Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both.

M L Kraybill1, E B Larson, D W Tsuang, L Teri, W C McCormick, J D Bowen, W A Kukull, J B Leverenz, M M Cherrier.   

Abstract

OBJECTIVE: To examine the neuropsychological profile of dementia patients from a community-based autopsy sample of dementia, comparing Alzheimer disease (AD), Lewy body pathology (LBP) alone, and LBP with coexistent AD (AD/LBP).
METHODS: The authors reviewed 135 subjects from a community-based study of dementia for whom autopsy and brain tissue was available. Diagnostic groups were determined according to standard neuropathologic methods and criteria, and the presence of LBs was determined using alpha-synuclein immunostaining. Neuropathologically defined diagnostic groups of AD, AD/LBP, and LBP were examined for differences on neuropsychological test performance at the time of initial study enrollment.
RESULTS: There were 48 patients with AD alone, 65 with LB and AD pathology (AD/LBP), and 22 with LBP alone (LBP alone). There were no significant differences between groups demographically or on performance of enrollment Mini-Mental State Examination (MMSE) or Dementia Rating Scale (DRS). AD patients performed worse than the LBP patients on memory measures (Fuld Object Memory Evaluation Delayed Recall, Wechsler Memory Scale Logical Memory Immediate and Delayed Recall; p < 0.05) and a naming task (Consortium to Establish a Registry for Alzheimer's Disease Naming; p < 0.05). LBP patients were more impaired than AD patients on executive function (Trail Making Test Part B; p < 0.05) and attention tasks (Wechsler Adult Intelligence Scale-Revised Digit Span; p < 0.05). Decline in MMSE and DRS scores over time were greatest in the patients with AD/LBP.
CONCLUSIONS: In a community-based sample of older, medically complicated patients with dementia, there are neuropsychological differences between dementia subtypes at the time of diagnosis. In particular, patients with Alzheimer disease (AD) alone and AD/Lewy body pathology (LBP) had more severe memory impairment than patients with LBP. LBP alone was associated with more severe executive dysfunction. Patients with AD/LBP had the most rapid rate of cognitive decline.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15985574      PMCID: PMC1513627          DOI: 10.1212/01.WNL.0000165987.89198.65

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

1.  University of Washington Alzheimer's Disease Patient Registry (ADPR): 1987-1988.

Authors:  E B Larson; W A Kukull; L Teri; W McCormick; M Pfanschmidt; G van Belle; M Sumi
Journal:  Aging (Milano)       Date:  1990-12

Review 2.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.

Authors:  I G McKeith; D Galasko; K Kosaka; E K Perry; D W Dickson; L A Hansen; D P Salmon; J Lowe; S S Mirra; E J Byrne; G Lennox; N P Quinn; J A Edwardson; P G Ince; C Bergeron; A Burns; B L Miller; S Lovestone; D Collerton; E N Jansen; C Ballard; R A de Vos; G K Wilcock; K A Jellinger; R H Perry
Journal:  Neurology       Date:  1996-11       Impact factor: 9.910

Review 3.  Early diagnosis of dementia: neuropsychology.

Authors:  F Pasquier
Journal:  J Neurol       Date:  1999-01       Impact factor: 4.849

4.  The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity.

Authors:  L Hansen; D Salmon; D Galasko; E Masliah; R Katzman; R DeTeresa; L Thal; M M Pay; R Hofstetter; M Klauber
Journal:  Neurology       Date:  1990-01       Impact factor: 9.910

5.  Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry.

Authors:  R L Hamilton
Journal:  Brain Pathol       Date:  2000-07       Impact factor: 6.508

6.  Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease.

Authors:  C F Lippa; M L Schmidt; V M Lee; J Q Trojanowski
Journal:  Ann Neurol       Date:  1999-03       Impact factor: 10.422

7.  Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX.

Authors:  A Heyman; G G Fillenbaum; M Gearing; S S Mirra; K A Welsh-Bohmer; B Peterson; C Pieper
Journal:  Neurology       Date:  1999-06-10       Impact factor: 9.910

8.  Cognitive decline is faster in Lewy body variant than in Alzheimer's disease.

Authors:  J M Olichney; D Galasko; D P Salmon; C R Hofstetter; L A Hansen; R Katzman; L J Thal
Journal:  Neurology       Date:  1998-08       Impact factor: 9.910

9.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

10.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.

Authors:  C F Lippa; H Fujiwara; D M Mann; B Giasson; M Baba; M L Schmidt; L E Nee; B O'Connell; D A Pollen; P St George-Hyslop; B Ghetti; D Nochlin; T D Bird; N J Cairns; V M Lee; T Iwatsubo; J Q Trojanowski
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

View more
  108 in total

1.  Everyday action impairment in Parkinson's disease dementia.

Authors:  Tania Giovannetti; Priscilla Britnell; Laura Brennan; Andrew Siderowf; Murray Grossman; David J Libon; Brianne M Bettcher; Francesca Rouzard; Joel Eppig; Gregory A Seidel
Journal:  J Int Neuropsychol Soc       Date:  2012-05-24       Impact factor: 2.892

Review 2.  Profile of cognitive impairment in Parkinson's disease.

Authors:  G Stennis Watson; James B Leverenz
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

3.  Risk of decline in functional activities in dementia with Lewy bodies and Alzheimer disease.

Authors:  Dawn P Gill; Thomas D Koepsell; Rebecca A Hubbard; Walter A Kukull
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Jan-Mar       Impact factor: 2.703

4.  Auditory confrontation naming in Alzheimer's disease.

Authors:  Jason Brandt; Arnold Bakker; David Aaron Maroof
Journal:  Clin Neuropsychol       Date:  2010-10-27       Impact factor: 3.535

5.  The organization and anatomy of narrative comprehension and expression in Lewy body spectrum disorders.

Authors:  Sharon Ash; Sharon X Xie; Rachel Goldmann Gross; Michael Dreyfuss; Ashley Boller; Emily Camp; Brianna Morgan; Jessica O'Shea; Murray Grossman
Journal:  Neuropsychology       Date:  2012-02-06       Impact factor: 3.295

6.  Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline.

Authors:  Lani K Clinton; Mathew Blurton-Jones; Kristoffer Myczek; John Q Trojanowski; Frank M LaFerla
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

7.  Effect of α-synuclein on amyloid β-induced toxicity: relevance to Lewy body variant of Alzheimer disease.

Authors:  Rosa Resende; Sueli C F Marques; Elisabete Ferreiro; Isaura Simões; Catarina R Oliveira; Cláudia M F Pereira
Journal:  Neurochem Res       Date:  2013-02-07       Impact factor: 3.996

8.  The new Qualitative Scoring MMSE Pentagon Test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease.

Authors:  Micaela Mitolo; David P Salmon; Simona Gardini; Douglas Galasko; Enzo Grossi; Paolo Caffarra
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

9.  APOE DNA methylation is altered in Lewy body dementia.

Authors:  Jessica Tulloch; Lesley Leong; Sunny Chen; C Dirk Keene; Steven P Millard; Andrew Shutes-David; Oscar L Lopez; Julia Kofler; Jeffrey A Kaye; Randy Woltjer; Peter T Nelson; Janna H Neltner; Gregory A Jicha; Douglas Galasko; Eliezer Masliah; James B Leverenz; Chang-En Yu; Debby Tsuang
Journal:  Alzheimers Dement       Date:  2018-03-12       Impact factor: 21.566

10.  Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies.

Authors:  Joanne M Hamilton; David P Salmon; Douglas Galasko; Rema Raman; Jenn Emond; Lawrence A Hansen; Eliezer Masliah; Leon J Thal
Journal:  Neuropsychology       Date:  2008-11       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.